Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
References (15)
- et al.
Effect of vasodilators on survival in chronic congestive heart failure
Am J Cardiol
(1985) - et al.
Treatment of chronic heart failure: A review of recent drug trials
Br Med J
(1985) - et al.
Effect of vasodilator therapy on mortality in chronic congestive heart failure
N Engl J Med
(1986) - et al.
Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure
Drugs
(1986) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
N Engl J Med
(1987)A method for the determination of the heart size by teleroentgenography (a heart volume index)
Acta Radiol
(1939)- et al.
International diagnostic criteria for acute myocardial infarction and acute stroke
Am Heart J
(1985)
There are more references available in the full text version of this article.
Cited by (145)
A review of the conservative versus invasive management of ischemic heart failure with reduced ejection fraction
2024, Current Problems in CardiologyImpact of vericiguat on heart failure with reduced ejection fraction: a review
2023, Global Health JournalRenin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology
2022, European Journal of Internal MedicineCitation Excerpt :Several and consistent data, from randomized controlled studies, have demonstrated the efficacy of RAAS blockade in HFrEF (Fig. 1). In 1998 the CONSENSUS study [4] firstly reported a 31% mortality risk reduction with enalapril in patients with advanced symptomatic HF; similarly, in the SOLVD trial [5] enalapril reduced by 16% all-cause mortality and by 26% the composite outcome of hospitalization due to HF (HHF) and death in patients with EF ≤35% and stable clinical conditions (NYHA class II/III). Subsequently, the trials SAVE [6], TRACE [7] and AIRE [8] confirmed the efficacy of captopril, trandolapril, and ramipril in post-myocardial infarction HF.
Diversity in modern heart failure trials: Where are we, and where are we going
2022, International Journal of CardiologyAntisense Inhibition of Angiotensinogen With IONIS-AGT-L<inf>Rx</inf>: Results of Phase 1 and Phase 2 Studies
2021, JACC: Basic to Translational Science
- a
See Appendix.
Copyright © 1988 Published by Elsevier Inc.